RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
Gardaí Seize €3M Of Illegal Vapes, Cannabis Products In Carlow And Other Counties
Dangerous Driving Videos Still Being Shown On TikTok
Twelve New Gardaí Allocated To Kildare, As Garda Numbers Hit All Time High
Gardaí Continue To Question Two People About Waterford Arson Attack
Yuno Energy Latest Company To Announce Winter Price Freeze
Kildare Minister Launches Ireland's First AI Research Institute
Gardaí Arrest Two People In Connection With Waterford Arson Attack
Jeffrey Donaldson To Be Sentenced For Historic Child Sex Offences Today
